Proactive’s Post

The largest biopharma companies have a market cap of ~$4 trillion. Here's a look behind the biggest swings over the last 10 years: The biggest and clearest gain is how GLP-1s have powered Lilly and Novo to market values magnitudes above everyone else. But this isn't just a story of GLP-1s carrying the team: The remaining 17 analyzed were able to grow market values from $2.1 trillion in 2019 to $2.7 trillion in 2024, showing there was good growth industry-wide. There are also several interesting sub-plots within the bigger picture: The contrast between Japan's two largest biopharma companies, Daiichi-Sankyo and Takeda, is particularly interesting. 10 years ago, Takeda had a market cap almost 3x higher than Daiichi Sankyo, which today has the larger market cap. Daiichi grew its value primarily through organic growth, particularly around oncology and ADCs, while Takeda's most notable move was its $62B acquisition of Shire in 2019. Daiichi has been particularly successful leveraging partnerships: Its 2019 deal with AstraZeneca for what became Enhertu got it $1.35B upfront, and a subsequent 2020 deal with AstraZeneca got it another $1B in guaranteed payments. Most recently, Daiichi signed a monster deal with Merck that included $4 billion in upfront and near term guaranteed payments for 3 ADCs. The rise of Regeneron and Vertex into the top tier of biopharmas is also notable. Both are now at key inflection points working to diversify their pipelines, with Vertex getting closer to launching its first medicines outside CF. Looking back, it's clear there is a lot of shifting up and down the list, which proves the old adage "the only constant is change", and shows the only way to remain on top is through consistent, impactful innovation.

The largest biopharma companies have a market cap of ~$4 trillion. Here's a look behind the biggest swings over the last 10 years: The biggest and clearest gain is how GLP-1s have powered Lilly and Novo to market values magnitudes above everyone else. But this isn't just a story of GLP-1s carrying the team: The remaining 17 analyzed were able to grow market values from $2.1 trillion in 2019 to $2.7 trillion in 2024, showing there was good growth industry-wide. There are also several interesting sub-plots within the bigger picture: The contrast between Japan's two largest biopharma companies, Daiichi-Sankyo and Takeda, is particularly interesting. 10 years ago, Takeda had a market cap almost 3x higher than Daiichi Sankyo, which today has the larger market cap. Daiichi grew its value primarily through organic growth, particularly around oncology and ADCs, while Takeda's most notable move was its $62B acquisition of Shire in 2019. Daiichi has been particularly successful leveraging partnerships: Its 2019 deal with AstraZeneca for what became Enhertu got it $1.35B upfront, and a subsequent 2020 deal with AstraZeneca got it another $1B in guaranteed payments. Most recently, Daiichi signed a monster deal with Merck that included $4 billion in upfront and near term guaranteed payments for 3 ADCs. The rise of Regeneron and Vertex into the top tier of biopharmas is also notable. Both are now at key inflection points working to diversify their pipelines, with Vertex getting closer to launching its first medicines outside CF. Looking back, it's clear there is a lot of shifting up and down the list, which proves the old adage "the only constant is change", and shows the only way to remain on top is through consistent, impactful innovation.

AstraZeneca 𝐡𝐚𝐬 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐝 𝐚𝐧 𝐚𝐦𝐛𝐢𝐭𝐢𝐨𝐮𝐬 𝐠𝐨𝐚𝐥 𝐭𝐨 𝐛𝐨𝐨𝐬𝐭 𝐢𝐭𝐬 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐛𝐲 𝟕𝟓% 𝐭𝐨 $𝟖𝟎 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟎. This growth is expected to be driven by the launch of 20 new medicines and the expansion of its current oncology, biopharmaceuticals, and rare disease portfolios. 𝐂𝐄𝐎 𝐏𝐚𝐬𝐜𝐚𝐥 𝐒𝐨𝐫𝐢𝐨𝐭, who has significantly revitalized the company's drug pipeline over the past decade, highlighted that many of these new medicines could each generate over $5 billion in peak year revenues. Despite facing patent expirations on some key drugs, AstraZeneca plans to invest in new technologies and platforms to sustain its growth beyond 2030. Analysts are keenly watching the company's investor day event for detailed insights into its pipeline assets and their market potential. https://lnkd.in/dZxxjuvF #PharmaGrowth #AstraZeneca #BiotechInnovation #NewMedicines #HealthcareInvestment #pharma

From GLP-1-driven market upheavals to strategic acquisitions and partnerships, the last decade in biopharma has seen dramatic shifts, with industry-wide growth and fascinating contrasts among top players. #Biopharma #MarketTrends #Innovation

The largest biopharma companies have a market cap of ~$4 trillion. Here's a look behind the biggest swings over the last 10 years: The biggest and clearest gain is how GLP-1s have powered Lilly and Novo to market values magnitudes above everyone else. But this isn't just a story of GLP-1s carrying the team: The remaining 17 analyzed were able to grow market values from $2.1 trillion in 2019 to $2.7 trillion in 2024, showing there was good growth industry-wide. There are also several interesting sub-plots within the bigger picture: The contrast between Japan's two largest biopharma companies, Daiichi-Sankyo and Takeda, is particularly interesting. 10 years ago, Takeda had a market cap almost 3x higher than Daiichi Sankyo, which today has the larger market cap. Daiichi grew its value primarily through organic growth, particularly around oncology and ADCs, while Takeda's most notable move was its $62B acquisition of Shire in 2019. Daiichi has been particularly successful leveraging partnerships: Its 2019 deal with AstraZeneca for what became Enhertu got it $1.35B upfront, and a subsequent 2020 deal with AstraZeneca got it another $1B in guaranteed payments. Most recently, Daiichi signed a monster deal with Merck that included $4 billion in upfront and near term guaranteed payments for 3 ADCs. The rise of Regeneron and Vertex into the top tier of biopharmas is also notable. Both are now at key inflection points working to diversify their pipelines, with Vertex getting closer to launching its first medicines outside CF. Looking back, it's clear there is a lot of shifting up and down the list, which proves the old adage "the only constant is change", and shows the only way to remain on top is through consistent, impactful innovation.

LARGEST BIOPHARMA COMPSNIES MSRKET CAPITALISATION SOARING AS HIGH AS $ 4 TRILLION The largest biopharma companies have a market cap of ~$4 trillion. Here's a look behind the biggest swings over the last 10 years: The biggest and clearest gain is how GLP-1s have powered Lilly and Novo to market values magnitudes above everyone else. But this isn't just a story of GLP-1s carrying the team: The remaining 17 analyzed were able to grow market values from $2.1 trillion in 2019 to $2.7 trillion in 2024, showing there was good growth industry-wide. There are also several interesting sub-plots within the bigger picture: The contrast between Japan's two largest biopharma companies, Daiichi-Sankyo and Takeda, is particularly interesting. 10 years ago, Takeda had a market cap almost 3x higher than Daiichi Sankyo, which today has the larger market cap. Daiichi grew its value primarily through organic growth, particularly around oncology and ADCs, while Takeda's most notable move was its $62B acquisition of Shire in 2019. Daiichi has been particularly successful leveraging partnerships: Its 2019 deal with AstraZeneca for what became Enhertu got it $1.35B upfront, and a subsequent 2020 deal with AstraZeneca got it another $1B in guaranteed payments. Most recently, Daiichi signed a monster deal with Merck that included $4 billion in upfront and near term guaranteed payments for 3 ADCs. The rise of Regeneron and Vertex into the top tier of biopharmas is also notable. Both are now at key inflection points working to diversify their pipelines, with Vertex getting closer to launching its first medicines outside CF. Looking back, it's clear there is a lot of shifting up and down the list, which proves the old adage "the only constant is change", and shows the only way to remain on top is through consistent, impactful innovation.

Ipsen steps into the #ADC arena with a strategic global licensing deal with Sutro Biopharma, Inc., securing exclusive rights to develop and commercialize STRO-003, a promising ROR1-targeting antibody-drug conjugate (#ADC). This move positions Ipsen at the forefront of oncology innovation, marking its entry with STRO-003 into the high-stakes world of ADCs. Under this partnership, #Sutro could net up to $900M in payments, highlighting the significant investment and belief in STRO-003's potential. #Ipsen will spearhead Phase I trials and oversee the #drug's journey from clinical development to global market presence. With ADCs becoming a hotbed of activity, Ipsen's venture represents a strategic alignment with industry trends, showcasing the immense potential and value within the ADC market. In recent months, giants like Johnson & Johnson and Bristol Myers Squibb have inked multi-billion dollar deals, emphasizing the growing importance of ADCs in oncology treatment. As Ipsen embarks on this journey with STRO-003, the pharmaceutical world watches closely, anticipating the impact of this collaboration on cancer treatment and ADC development. Connect, Repost & Follow for more info on the pharmaceutical industry 🌍 #pharma #pharmaceutical #pharmaindustry #europe #pharmaceuticalindustry #healthcare

In the coming years, Bristol Myers Squibb, Merck, Amgen, Novartis, and AstraZeneca will experience the highest level of exposure to generic and biosimilar competition, while Vertex, Gilead Sciences, Sanofi, Novo Nordisk, and Eli Lilly will be the least exposed over the 2025-2030 timeframe. From 2030 onward, however, Lilly, Gilead, and Novo are much more likely to take a hit from LOEs alongside companies like Regeneron and Biogen. Vertex, GSK, Pfizer, Takeda, and Amgen are likely to fare the best in terms of LOE exposure from 2030 through 2040. Naturally, companies are eagerly looking to acquire external high rNPV products with the potential to launch in the near term in addition to bolstering their internal R&D pipelines. The hunt for the next generation of blockbusters is on; JPM2025 promises to be fun! Yet, not every blockbuster hopeful will make it to the finish line. It would be okay if the only reason science-based products did not reach their expected potential was because of the biological variables. Today, with the ability to anticipate challenges, plan for alternative scenarios in approvals, reimbursements, and launches, and make predictive decisions to navigate future obstacles, operational variables should no longer limit the potential of years of R&D. Patients should not miss out on timely access to medicines due to preventable delays. Takeaway: The life of a drug is short; make every day count! More here: https://lnkd.in/gzJ4S5bT Reference: https://lnkd.in/gcXghPgz

Looking at the 20 top pharma companies by market cap reveals some clear trends, yet others are more subtle: While Eli Lilly and Novo Nordisk have long been in the top 20, only in the last ~2 years have they broken into the top tier, thanks to their GLP-1s. Lilly is now amongst the 10 most valuable companies in the world, across all industries. While weight loss drugs have gotten the headlines, others delivered impressive gains over the last 3 years as well: AstraZeneca increased its value by ~50%, largely thanks to its strong oncology portfolio, with blockbusters like Tagrisso that delivered ~$6B in sales in FY2023. Meanwhile, Regeneron and Vertex almost doubled their value, driven by Dupixent/Eylea and Trikafta respectively. One of the most surprising results is from AbbVie, which increased its market cap from ~$200B to ~$300B in the last 3 years, despite the fact its best-seller Humira began to face competition during that time.